Recurrent facial keratoacanthoma in a patient with diabetes: a case report

BMC Research Notes

Esam Omar¹ 

[1] Oral & Maxillofacial Surgery, College of Dentistry, Taibah University, Almadinah, Saudi Arabia

关键词: Recurrent keratoacanthoma;    Report;   

Others  :  1133262
DOI  :  10.1186/1756-0500-7-257

 received in 2013-07-13, accepted in 2014-04-16,  发布年份 2014

【 摘 要 】

Background

Keratoacanthoma is a relatively common low-grade malignancy that originates in the pilosebaceous glands. Pathologically, it closely resembles squamous cell carcinoma. Keratoacanthoma is believed to have a good prognosis; however, it has been reclassified as squamous cell carcinoma, keratoacanthoma type, to reflect the difficulty in histologic differentiation of this lesion as well as its uncommon but potentially aggressive nature. Keratoacanthoma infrequently presents as multiple tumors and may enlarge (5–15 cm), become locally aggressive, and rarely metastasize.

Case presentation

A 66-year-old Arab male patient with diabetes was referred to the Maxillofacial Surgery Department with a chief complaint of a dome-shaped nodule with a smooth, shiny surface and central crateriform ulceration with a keratin plug in the form of a horn-like projection. Skin papules were present in the right lateral canthal area and extended to the lateral border of the lower eyelid, measuring 1.3 cm. On palpation, the lesion was firm, movable, and tender. The patient had a history of a similar lesion in another area of his face that had spontaneously regressed.

Conclusion

Histological differentiation between keratoacanthoma and well-differentiated squamous cell carcinoma is difficult, particularly when a secondary infection is present. Careful establishment of the correlation among the history, clinical findings, and histopathology is highly indicated to avoid unnecessary surgical intervention.

【 授权许可】

   
2014 Omar; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Manstein CH, Frauenhoffer CJ, Besden JE: Keratoacanthoma: is it a real entity? Ann Plast Surg 1998, 40(5):469-472.
• [2]Schwartz RA: Keratoacanthoma. J Am Acad Dermatol 1994, 30(1):1-19.
• [3]Magalhaes RF, Cruvinel GT, Cintra GF, Cintra ML, Ismael AP, de Moraes AM: Diagnosis and follow-up of keratoacanthoma-like lesions: clinical-histologic study of 43 cases. J Cutan Med Surg 2008, 12(4):163-173.
• [4]Kossard S, Tan KB, Choy C: Keratoacanthoma and infundibulocystic squamous cell carcinoma. Am J Dermatopathol 2008, 30(2):127-134.
• [5]Frank TL, Maguire HC Jr, Greenbaum SS: Multiple painful keratoacanthomas. Int J Dermatol 1996, 35(9):648-650.
• [6]Sanders S, Busam KJ, Halpern AC, Nehal KS: Intralesional corticosteroid treatment of multiple eruptive keratoacanthomas: case report and review of a controversial therapy. Dermatol Surg 2002, 28(10):954-958.
• [7]Chuang TY, Reizner GT, Elpern DJ, Stone JL, Farmer ER: Non-melanoma skin cancer and keratoacanthoma in Filipinos: an incidence report from Kauai, Hawaii. Int J Dermatol 1993, 32(10):717-718.
• [8]Chuang TY, Reizner GT, Elpern DJ, Stone JL, Farmer ER: Keratoacanthoma in Kauai, Hawaii. The first documented incidence in a defined population. Arch Dermatol 1993, 129(3):317-319.
• [9]Reizner GT, Chuang TY, Elpern DJ, Stone JL, Farmer ER: Basal cell carcinoma and keratoacanthoma in Hawaiians: an incidence report. J Am Acad Dermatol 1993, 29(5 Pt 1):780-782.
• [10]Annest NM, VanBeek MJ, Arpey CJ, Whitaker DC: Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective study and review of the literature. J Am Acad Dermatol 2007, 56(6):989-993.
• [11]Sayama S, Tagami H: Treatment of keratoacanthoma with intralesional bleomycin. Br J Dermatol 1983, 109(4):449-452.
• [12]Dendorfer M, Oppel T, Wollenberg A, Prinz JC: Topical treatment with imiquimod may induce regression of facial keratoacanthoma. Eur J Dermatol 2003, 13(1):80-82.
• [13]Canas GC, Robson KJ, Arpey CJ, Canas GC, Robson KJ, Arpey CJ: Persistent keratoacanthoma: challenges in management. Dermatol Surg 1998, 24(12):1364-1369.